Genetic variation and pharmacogenomics: Concepts, facts, and challenges

Dialogues in Clinical Neuroscience

Volumn 6, Issue 1, 2004, Pages 5-26

  Hoehe, Margret R ^a   Kroslak, Thomas ^a  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

Candidate gene; DNA sequence; Drug response; Genetic variation; Haplotype; Single nucleotide polymorphism

Indexed keywords

DNA SEQUENCE; GENE FUNCTION; GENE IDENTIFICATION; GENE SEQUENCE; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN GENOME; MOLECULAR GENETICS; PHARMACOGENOMICS; PHENOTYPE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 1842458491     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. 2-adrenergic receptor and their putative promoter regions. J Biol Chem. 1987;262:7321-7327.
2. Bradshaw RA, Dennis E. Handbook of Cell Signaling. New York, NY: Academic Press;. 2003.
3. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3:639-650.
4. Drews J. Genomic sciences and the medicine of tomorrow. Nat Biotechnol. 1996;14:1516-1518.
5. 2-adrenergic receptor function. J Allergy Clin Immunol. 1999;104:S42-S46.
6. Hoehe MR. Project Proposal. A Genotype Approach: The Investigation of Inter-individual DNA Sequence Differences in Adrenergic Receptor Genes and Their Possible Functional Implications. http://www.molgen.mpg.de/~genetic_variation_program/ Accessed 21 January 2004.
7. Mansfield BK. The Genome Project and the pharmaceutical industry. Hum Genome News. 1990:10-11.
8. Garrod AE. Inborn Errors of Metabolism. New York, NY: Oxford University Press; 1909.
9. Nebert DW. Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants. Clin Chem Lab Med. 2000;38:857-861.
10. Weiss KM. Is there a paradigm shift in genetics? Lessons from the study of human diseases. Mol Phylogenet Evol. 1996;5:259-265.
11. Cohen J. Developing prescriptions with a personal touch. Science. 1997;275:776.
12. Marshall A. Laying the foundations for personalized medicines. Nat Biotechnol. 1997;15:954-957.
13. Marshall A. Getting the right drug into the right patient. Nat Biotechnol. 1997;15:1249-1252.
14. Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000;405:857-865.
15. Collins FS. Positional cloning moves from perditional to traditional. Nat Genet. 1995;9:347-350.
16. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291:1304-1351.
17. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921.
18. Collins FS, Guyer MS, Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science. 1997;278:1580-1581.
19. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409:928-933.
20. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-resolution haplotype structure in the human genome. Nat Genet. 2001;29:229-232.
21. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002;296:2225-2229.
22. Patil N, Berno AJ, Hinds DA, et al. Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science. 2001;294:1719-1723.
23. Reich DE, Cargill M, Bolk S, et al. Linkage disequilibrium in the human genome. Nature. 2001;411:199-204.
24. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A. 2000;97:10483-10488.
25. Fullerton SM, Clark AG, Weiss KM, et al. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet. 2000;67:881-900.
26. Gilad Y, Rosenberg S, Przeworski M, Lancet D, Skorecki K. Evidence for positive selection and population structure at the human MAO-A gene. Proc Natl Acad Sci U S A. 2002;99:862-867.
27. Harding RM, Fullerton SM, Griffiths RC, et al. Archaic African and Asian lineages in the genetic ancestry of modern humans. Am J Hum Genet. 1997;60:772-789.
28. Harris EE, Hey J. X chromosome evidence for ancient human histories. Proc Natl Acad Sci U S A. 1999;96:3320-3324.
29. Hoehe MR, Kopke K, Wendel B, et al. Sequence variability and candidate gene analysis in complex disease: association of μ opioid receptor gene variation with substance dependence. Hum Mol Genet. 2000;9:2895-2908.
30. Nickerson DA, Taylor SL, Fullerton SM, et al. Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene. Genome Res. 2000;10:1532-1545.
31. Nickerson DA, Taylor SL, Weiss KM, et al. DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene. Nat Genet. 1998;19:233-240.
32. Rieder MJ, Taylor SL, Clark AG, Nickerson DA. Sequence variation in the human angiotensin-converting enzyme. Nat Genet. 1999;22:59-62.
33. Stephens JC, Schneider JA, Tanguay DA, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science. 2001;293:489-493.
34. Toomajian C, Kreitman M. Sequence variation and haplotype structure at the human HFE locus. Genetics. 2002;161:1609-1623.
35. Chakravarti A. It's raining SNPs, hallelujah? Nat Genet. 1998;19:216-217.
36. Halushka MK, Fan JB, Bentley K, et al. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet. 1999;22:239-247.
37. Cargill M, Altshuler D, Ireland J, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999;22:231-238.
38. Clark AG, Weiss KM, Nickerson DA, et al. Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase. Am J Hum Genet. 1998;63:595-612.
39. Hoehe MR. Haplotypes and the systematic analysis of genetic variation in genes and genomes. Pharmacogenomics. 2003;4:547-570.
40. Ackenheil M, Weber K. Differing response to antipsychotic therapy in schizophrenia: pharmacogenomic aspects. Dialogues Clin Neurosci. 2004;6:71-77.
41. Morris-Rosendahl, DJ, Fiebich BL. The future of genetic testing for drug response. Dialogues Clin Neurosci. 2004;6:27-37.
42. Altshuler D, Pollara VJ, Cowles CR, et al. An SNP map of the human genome generated by reduced representation shotgun sequencing. Nature. 2000;407:513-516.
43. Mullikin JC, Hunt SE, Cole CG, et al. An SNP map of human chromosome 22. Nature. 2000;407:516-520.
44. Wang DG, Fan JB, Siao CJ, et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science. 1998;280:1077-1082.
45. Marth GT, Korf I, Yandell MD, et al. A general approach to single-nucleotide polymorphism discovery. Nat Genet. 1999;23:452-456.
46. Johnson GC, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common disease genes. Nat Genet. 2001;29:233-237.
47. NIH Meeting on Developing a Haplotype Map of the Human Genome for Finding Genes Related to Health and Disease, Bethesda, Md, July 18-19, 2001.
48. Judson R, Stephens JC, Windemuth A. The predictive power of haplotypes in clinical response. Pharmacogenomics. 2000;1:15-26.
49. Kidd KK, Pakstis AJ, Castiglione CM, et al. DRD2 haplotypes containing the Taql A1 allele: implications for alcoholism research. Alcohol Clin Exp Res. 1996;20:697-705.
50. Templeton AR, Clark AG, Weiss KM, Nickerson DA, Boerwinkle E, Sing CF. Recombinational and mutational hotspots within the human lipoprotein lipase gene. Am J Hum Genet. 2000;66:69-83.
51. Davidson S. Research suggests importance of haplotypes over SNPs. Nat Biotechnol. 2000;18:1134-1135.
52. Joosten PH, Toepoel M, Mariman EC, Van Zoelen EJ. Promoter haplotype combinations of the platelet-derived growth factor alpha-receptor gene predispose to human neural tube defects. Nat Genet. 2001;27:215-217.
53. Taton TA, Mirkin CA. Haplotyping by force. Nat Biotechnol. 2000;18:713.
54. Wood NA, Keen LJ, Tilley LA, Bidwell JL. Determination of cytokine regulatory haplotypes by induced heteroduplex analysis of DNA. J Immunol Methods. 2001;249:191-198.
55. Hoehe MR, Timmermann B, Lehrach H. Haplotypes and the systematic analysis of genetic variation: disease genes, drug targets and pharmacogenomics [in German]. Biospektrum. 2002;8:478-485.
56. Timmermann B, Mo R, Luft FC, et al. Beta adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney Int. 1998;53:1455-1460.
57. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994;33:9414-9419.
58. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 1993;268:23116-23121.
59. 2 adrenergic receptor mRNA inhibits receptor synthesis. J Biol Chem. 1994;269:4497-4505.
60. 2-adrenoceptor. Hypertension. 1997;30:773-776.
61. 2-adrenergic receptor regulate receptor expression. J Clin Invest. 1998;102:1927-1932.
62. Hoehe MR, Rinn T, Flachmeier C, et al. Comparative sequencing of the human CB1 cannabinoid receptor gene coding exon: no structural mutations in individuals exhibiting extreme responses to cannabis. Psychiatr Genet. 2000;10:173-177.
63. Rioux JD, Daly MJ, Silverberg MS, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet. 2001;29:223-228.
64. Rana BK, Hewett-Emmett D, Jin L, et al. High polymorphism at the human melanocortin 1 receptor locus. Genetics. 1999;151:1547-1557.
65. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
66. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845-857.
67. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
68. Branson R, Potoczna N, Kral JG, Lentes KU, Hoehe MR, Horber FF. Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. N Engl J Med. 2003;348:1096-1103.
69. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet. 2000;26:163-175.
70. Hoehe MR, Timmermann B, Reinhardt R, Ott J, Lehrach H, Church GM. Haplotypes, in depth variation analysis, and the future of the analysis of genotype-phenotype relationships. Cold Spring Harbor Meeting. The Biology of DNA. Cold Spring Harbor, NY, February 26-March 2;2003:45.
71. Li WH, Sadler LA. Low nucleotide diversity in man. Genetics. 1991;129:513-523.
72. Sunyaev SR, Lathe WC III, Ramensky VE, Bork P. SNP frequencies in human genes an excess of rare alleles and differing modes of selection. Trends Genet. 2000;16:335-337.
73. Grantham R. Amino acid difference formula to help explain protein evolution. Science. 1974;185:862-864.
74. Harris H, Hopkinson DA. Average heterozygosity per locus in man: an estimate based on the incidence of enzyme polymorphisms. Ann Hum Genet. 1972;36:9-20.
75. Eyre-Walker A, Keightley PD. High genomic deleterious mutation rates in hominids. Nature. 1999;397:344-347.
76. Li WH. Molecular Evolution. Sunderland, Mass: Sinauer Associates; 1997
77. Nei M. Molecular Evolutionary Genetics. New York, NY: Columbia University Press; 1987.
78. Fullerton SM, Clark AG, Weiss KM, et al. Sequence polymorphism at the human apolipoprotein All gene (APOA2): unexpected deficit of variation in an African-American sample. Hum Genet. 2002;111:75-87.
79. Harris EE, Hey J. Human populations show reduced DNA sequence variation at the factor IX locus. Curr Biol. 2001;11:774-778.
80. Hoehe MR, Timmermann B, Lehrach H. Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and implications for pharmacogenomics. Curr Pharm Biotechnol. 2003;4:351-378.
81. 1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Med. 2000;78:87-93.
82. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human μ-opioid receptor severely impairs receptor signaling. J Biol Chem. 2001;276:3130-3137.
83. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human μ-opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998;95:9608-9613.
84. Wilson JF, Weale ME, Smith AC, et al. Population genetic structure of variable drug response. Nat Genet. 2001;29:265-269.
85. Lichter J, McNamara D. What's in a gene: using genetic information for the design of clinical trials. Curr Opin Biotechnol. 1995;6:715-717.
86. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000;356:1667-1671.
87. Ferrari P. Pharmacogenomics: a new approach to individual therapy of hypertension? Curr Opin Nephrol Hypertens. 1998;7:217-222.
88. Lindpaintner K. Pharmacogenetics and the future of medical practice: conceptual considerations. Pharmacogenomics J. 2001;1:23-26.
89. Lindpaintner K. The importance of being modest-reflections on the pharmacogenetics of abacavir. Pharmacogenomics. 2002;3:835-838.
90. Terwilliger JD, Weiss KM. Linkage disequilibrium mapping of complex disease: fantasy or reality? Curr Opin Biotechnol. 1998;9:578-594.
91. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273:1516-1517.
92. Lander ES. The new genomics: global views of biology. Science. 1996;274:536-539.
93. Zhao H, Pfeiffer R, Gail MH. Haplotype analysis in population genetics and association studies. Pharmacogenomics. 2003;4:171-178.
94. Reich DE, Lander ES. On the allelic spectrum of human disease. Trends Genet. 2001;17:502-510.
95. Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet. 2001;69:124-137.
96. Pritchard JK, Cox NJ. The allelic architecture of human disease genes: common disease-common variant ... or not? Hum Mol Genet. 2002;11:2417-2423.
97. Weiss KM, Terwilliger JD. How many diseases does it take to map a gene with SNPs? Nat Genet. 2000;26:151-157.
98. Lander ES, Schork NJ. Genetic dissection of complex traits. Science. 1994;265:2037-2048.
99. Persidis A. The business of pharmacogenomics. Nat Biotechnol. 1998;16:209-210.
100. Schork NJ, Cardon LR, Xu X. The future of genetic epidemiology. Trends Genet. 1998;14:266-272